Equity
€20,417 ▲ 1.8%
Adkg paid out €18,571 in dividends. That is 98% of the 2025 profit.
Adkg
Lifetime
7 annual accounts with figures on one time axispeak €54,103 (2020)
€28,317▼ 26.1%
lowest -€33,366 (2019)
€18,935▼ 36.6%
peak €23,918 (2021)
€20,417▲ 1.8%
€22,963▼ 33.5%
Board2 names since 2018
2 directors and 1 other
Documentsfilings and deeds
25-08-202625 days late
2025micro format
Gross margin from €38,330 to €28,317Result from €29,868 to €18,935Company renamed from PHARMACIE DAILLY to Adkg 11-02Dividend €18,571Debts from €34,515 to €22,963Investments €2,377
Key points
from the 2025 annual accountsInvestments
€2,527 23.5 × depreciation
Green is investment, beige is depreciation.
Filings
7 annual accounts 5 late
The 2019 accounts came latest: 61 days after the end of the period.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as Adkg has now. Each dot stands for 68 companies, two years later.
94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for Adkg. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Manager
Director
- 99 sharesdeed of 05-06-2018
- 1 sharedeed of 05-06-2018
Recent changes
Company renamed from PHARMACIE DAILLY to Adkg
Registered office moved to Laeken · New registered office: Rue Emile Delva 73A à 1020 Laeken · Change of role: , from manager to director · General meeting of 29-01-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0697568768
Incorporation
Founding capital of €18,600, 100 shares · Founders: (partner) and (partner) · Appointment: (manager) · published on 05-06-2018 · Gazette deed
First establishment
PHARMACIE DAILLY, Daillylaan 41, Schaerbeek
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Adkg Brussels | €43,380 | €28,317 | 47.1% | - |
| Custers Elke Maaseik | €47,233 | €31,315 | 76.8% | - |
| VANFLETEREN PIETER Antwerp | €52,894 | €36,548 | 69.8% | - |
| Benisa BV Dilsen-Stokkem | €60,407 | €25,763 | 94.8% | - |
| DEL PHARMA Mons | €36,943 | €19,174 | 44.1% | - |
| Lies Goderis Moorslede | €48,634 | €20,633 | 80.7% | - |
| NIEMEGEERS KAROLIEN Bonheiden | €61,719 | €36,058 | 30.1% | - |
These companies have the same main activity as Adkg: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €36,900 and €61,700, founded between 2018 and 2020.
Official details
Source: KBO- Status
- Active since 01-06-2018Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.277.994.0251030 Schaerbeek, since 01-06-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 15-07-2024
Insights on Adkg
Adkg files the micro format. That format states no turnover. The gross margin rose from -€30,496 in 2019 to €28,317 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Adkg
- What is the company number of Adkg?
- The company number of Adkg is 0697.568.768. The VAT number is the same number with BE in front: BE 0697.568.768.
- Where is Adkg based?
- The registered office is at Emile Delvastraat 73A, 1020 Brussels.Company details
- What does Adkg do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Adkg?
- Adkg is a private limited company (BV).
- When was Adkg founded?
- Adkg was founded on 01-06-2018.
- Is Adkg still active?
- Yes, Adkg is an active enterprise in the KBO register.
- What is the turnover of Adkg?
- The turnover in financial year 2025 is ≈ €140,000. This figure is estimated from the gross margin of €28,317 and 51 comparable companies (NACE 477). It probably lies between €73,000 and €240,000.Financials
- Is Adkg profitable?
- In financial year 2025, Adkg made a profit of €18,935.
- Where can I find the annual accounts of Adkg?
- Adkg filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Adkg due?
- Adkg must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.